Nivolumab

Who we are

  • April 5, 2022
    SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
  • April 5, 2022
    Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
  • April 5, 2022
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
  • April 5, 2022
    Ipilimumab, Maraviroc and Nivolumab (LUMINESCENCE)
  • April 5, 2022
    Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
  • April 5, 2022
    METIMMOX: Colorectal Cancer METastasis – Shaping Anti-tumor IMMunity by OXaliplatin
  • April 5, 2022
    Nivolumab+Ipilimumab+RT in MSS mCRC
  • April 5, 2022
    Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
  • April 5, 2022
    Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer